Company research
Kairos Pharma, LTD.
CIK 1962011Updated Nov 6, 2026
SecurityKAPA · NYSE_AMERICAN · equity
KAPA price & chart
Loading TradingView…
AMEX:KAPA on TradingView ↗In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.03, 5.03, 7.01, 9.01
Show 5 more recent filings
10-Q filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 8,066,000Source | 5,004,000Source | 4,456,000Source | 6,673,000Source | — | 5,744,000Source | 7,937,000Source | — | 6,540,000Source | 5,768,000Source | 965,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 102,000Source | 262,000Source | — | 142,000Source | — | 22,000Source | 182,000Source | — | 62,000Source | 222,000Source | 382,000Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,575,000Source | — | 2,626,000Source | 3,034,000Source | — | 3,675,000Source | 3,616,000Source | — | 4,491,000Source | — | — |
| Assets, CurrentUSD | 6,656,000Source | 4,742,000Source | 3,174,000Source | 4,839,000Source | — | 4,443,000Source | 6,050,000Source | — | 5,387,000Source | 4,169,000Source | 101,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 24,000Source | 10,000Source | 136,000Source | 88,000Source | — | 143,000Source | 55,000Source | — | 51,000Source | 38,000Source | 8,000Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | — | 1,672,000Source | — | — | — | — | — | — | — | 992,000Source | 3,043,000Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 21,000Source | 13,000Source | 21,000Source | 18,000Source | — | 21,000Source | 16,000Source | — | 21,000Source | 14,000Source | 11,000Source |
| Additional Paid in CapitalUSD | 20,540,000Source | 11,154,000Source | 21,474,000Source | 17,478,000Source | — | 21,208,000Source | 16,709,000Source | — | 20,582,000Source | 13,577,000Source | 4,123,000Source |
| Retained Earnings (Accumulated Deficit)USD | -12,897,000Source | -7,835,000Source | -17,304,000Source | -11,499,000Source | — | -15,916,000Source | -10,077,000Source | — | -14,262,000Source | -8,815,000Source | -6,212,000Source |
| Stockholders' Equity Attributable to ParentUSD | 7,664,000Source | 3,332,000Source | 4,191,000Source | 5,997,000Source | -2,654,000Source | 5,313,000Source | 7,132,000Source | -2,401,000Source | 6,341,000Source | 4,776,000Source | -2,078,000Source |
| Liabilities and EquityUSD | 8,066,000Source | 5,004,000Source | 4,456,000Source | 6,673,000Source | — | 5,744,000Source | 7,937,000Source | — | 6,540,000Source | 5,768,000Source | 965,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 402,000Source | 1,672,000Source | 265,000Source | 676,000Source | — | 431,000Source | 805,000Source | — | 199,000Source | 992,000Source | 2,405,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,036,000Source | -714,000Source | -3,441,000Source | -3,955,000Source | 81,000Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 220,000Source | 3,058,000Source | 6,660,000Source | 5,134,000Source | -425,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -816,000Source | 2,344,000Source | 3,219,000Source | 1,179,000Source | -344,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 5,575,000Source | 3,217,000Source | 2,626,000Source | 3,034,000Source | 3,675,000Source | 3,616,000Source | 4,491,000Source | 1,272,000Source | 93,000Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 3,000Source | — |
| Additional Financial Items | |||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 40,000Source | 40,000Source | 160,000Source | 160,000Source | 160,000Source |
| General and Administrative ExpenseUSD | — | — | 827,000Source | 369,000Source | 798,000Source | 960,000Source | 1,006,000Source | 773,000Source | 3,437,000Source | 1,929,000Source | 1,632,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | — | 12,000Source | — | — | — | — | — | 35,000Source | 42,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,398,000Source | -1,047,000Source | -1,388,000Source | -1,422,000Source | -1,654,000Source | -1,262,000Source | -5,447,000Source | -2,603,000Source | -1,812,000Source |
| Nonoperating Income (Expense)USD | — | — | 37,000Source | -664,000Source | 29,000Source | 34,000Source | 36,000Source | 4,000Source | 125,000Source | -260,000Source | -98,000Source |
| Operating ExpensesUSD | — | — | 1,435,000Source | 383,000Source | 1,417,000Source | 1,456,000Source | 1,690,000Source | 1,266,000Source | 5,572,000Source | 2,343,000Source | 1,714,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | 165,000Source | — | — | 390,000Source | 425,000Source |
| Amortization of Deferred Charges | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -1,435,000Source | -383,000Source | -1,417,000Source | -1,456,000Source | -1,690,000Source | -1,266,000Source | -5,572,000Source | -2,343,000Source | -1,714,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,398,000Source | -1,047,000Source | -1,388,000Source | -1,422,000Source | -1,654,000Source | -1,262,000Source | -5,447,000Source | -2,603,000Source | -1,812,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.07Source | -0.1Source | -0.06Source | -0.08Source | -0.08Source | -0.08Source | -0.3Source | -0.23Source | -0.17Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.07Source | -0.1Source | -0.06Source | -0.08Source | -0.08Source | -0.08Source | -0.3Source | -0.23Source | -0.17Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 20,206,033Source | 10,910,227Source | 21,420,479Source | 17,213,017Source | 21,010,132Source | 15,875,485Source | 18,427,787Source | 11,356,451Source | 10,382,515Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 20,206,033Source | 10,910,227Source | 21,420,479Source | 17,213,017Source | 21,010,132Source | 15,875,485Source | 18,427,787Source | 11,356,451Source | 10,382,515Source |
| Interest Expense (non-operating)USD | — | — | — | 12,000Source | — | — | — | — | — | 35,000Source | 42,000Source |
| Additional Financial Items | |||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 40,000Source | 40,000Source | 160,000Source | 160,000Source | 160,000Source |
| General and Administrative ExpenseUSD | — | — | 827,000Source | 369,000Source | 798,000Source | 960,000Source | 1,006,000Source | 773,000Source | 3,437,000Source | 1,929,000Source | 1,632,000Source |
| Investment Income, NetUSD | — | — | 37,000Source | — | 29,000Source | 34,000Source | 36,000Source | 4,000Source | 125,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 37,000Source | -664,000Source | 29,000Source | 34,000Source | 36,000Source | 4,000Source | 125,000Source | -260,000Source | -98,000Source |
| Operating ExpensesUSD | — | — | 1,435,000Source | 383,000Source | 1,417,000Source | 1,456,000Source | 1,690,000Source | 1,266,000Source | 5,572,000Source | 2,343,000Source | 1,714,000Source |
| Research and Development ExpenseUSD | — | — | 608,000Source | 14,000Source | 619,000Source | 496,000Source | 684,000Source | 493,000Source | 2,135,000Source | 414,000Source | 82,000Source |
Offerings
Registration 333-292686
Filing attachments
ex99-1.htm · 8-K · 2026-11-05
Exhibit 99.1 Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Company’s lead candidate ENV-105 has been selected as winner of the Cancer Immunology Solution of the Year Award LOS ANGELES - November 5, 2026 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its…
Read attachment ↗ex99-2.htm · 8-K · 2026-11-03
Exhibit 99.2 Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development Houston conference serves as a platform devoted to advancing the field of basic, preclinical, and translational cancer research LOS ANGELES - November 3, 2026 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, announces that Neil Bhowmick, President and Chief Scientific Officer, presents …
Read attachment ↗ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer LOS ANGELES - October 6, 2026 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castratio…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-21
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Kairos Pharma Announces 1-for-7 Reverse Stock Split LOS ANGELES - August 21, 2026 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:0…
Read attachment ↗